Segui
Moises Diago
Moises Diago
Profesor Titular de Medicina
Email verificata su uv.es
Titolo
Citata da
Citata da
Anno
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
MW Fried, ML Shiffman, KR Reddy, C Smith, G Marinos, FL Gonçales Jr, ...
New England journal of medicine 347 (13), 975-982, 2002
86662002
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
SJ Hadziyannis, H Sette Jr, TR Morgan, V Balan, M Diago, P Marcellin, ...
Annals of internal medicine 140 (5), 346-355, 2004
39882004
Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis
E Vilar-Gomez, Y Martinez-Perez, L Calzadilla-Bertot, A Torres-Gonzalez, ...
Gastroenterology 149 (2), 367-378. e5, 2015
21672015
Telaprevir for retreatment of HCV infection
S Zeuzem, P Andreone, S Pol, E Lawitz, M Diago, S Roberts, R Focaccia, ...
New England Journal of Medicine 364 (25), 2417-2428, 2011
21252011
Peginterferon alfa-2a in patients with chronic hepatitis C
S Zeuzem, SV Feinman, J Rasenack, EJ Heathcote, MY Lai, E Gane, ...
New England Journal of Medicine 343 (23), 1666-1672, 2000
17262000
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
P Marcellin, GKK Lau, F Bonino, P Farci, S Hadziyannis, R Jin, ZM Lu, ...
New England Journal of Medicine 351 (12), 1206-1217, 2004
15282004
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
The Lancet 394 (10215), 2184-2196, 2019
10752019
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
M Romero-Gómez, MDM Viloria, RJ Andrade, J Salmerón, M Diago, ...
Gastroenterology 128 (3), 636-641, 2005
9282005
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
P Ferenci, MW Fried, ML Shiffman, CI Smith, G Marinos, FL Gonçales Jr, ...
Journal of hepatology 43 (3), 425-433, 2005
6752005
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin
MG Swain, MY Lai, ML Shiffman, WGE Cooksley, S Zeuzem, DT Dieterich, ...
Gastroenterology 139 (5), 1593-1601, 2010
5152010
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
JM Sánchez–Tapias, M Diago, P Escartín, J Enríquez, M Romero–Gómez, ...
Gastroenterology 131 (2), 451-460, 2006
4742006
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
S Zeuzem, M Diago, E Gane, KR Reddy, P Pockros, D Prati, M Shiffman, ...
Gastroenterology 127 (6), 1724-1732, 2004
3592004
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
T Poynard, M Colombo, J Bruix, E Schiff, R Terg, S Flamm, ...
Gastroenterology 136 (5), 1618-1628. e2, 2009
3382009
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
F Bonino, P Marcellin, GKK Lau, S Hadziyannis, R Jin, T Piratvisuth, ...
Gut 56 (5), 699-705, 2007
3192007
Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C
M Romero-Gómez, CM Fernández-Rodríguez, RJ Andrade, M Diago, ...
Journal of hepatology 48 (5), 721-727, 2008
2302008
Peginterferon alfa-2a (40 kD)(PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining …
SJ Hadziyannis, H Cheinquer, T Morgan, M Diago, DM Jensen, H Sette, ...
Elsevier Science Bv, 2002
2232002
Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected …
M Diago, G Castellano, J Garcia-Samaniego, C Perez, I Fernandez, ...
Gut 55 (3), 374-379, 2006
1982006
Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study
MW Fried, ML Shiffman, RK Reddy, C Smith, G Marino, F Goncales, ...
Gastroenterology 5 (120), A55, 2001
1942001
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
JL Calleja, J Crespo, D Rincón, B Ruiz-Antorán, I Fernandez, C Perelló, ...
Journal of hepatology 66 (6), 1138-1148, 2017
1912017
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa‐2a plus ribavirin
M Romero‐Gómez, M Diago, RJ Andrade, JL Calleja, J Salmerón, ...
Hepatology 50 (6), 1702-1708, 2009
1872009
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20